NAD+, MOTS-c, and 5-Amino-1MQ: separating hype from human data

What did @dereklifts2 actually say?

Derek walked through a three-compound stack, calling it an energy blend built around synergy. His core argument: NAD+ is the fuel, MOTS-c increases mitochondrial demand for that fuel by triggering biogenesis through AMPK, and 5-Amino-1MQ blocks NNMT, the enzyme he says "basically drains all your storage of NAD+." The framing is mechanistically coherent, and he deserves credit for not leaning on testimonials or before-and-after photos. He kept this to mechanisms, which is the right place to start.

He also made a specific claim about fat loss stalls: "If you ever hit a stall in a fat loss phase, NNMT levels tend to be rising." That is a more targeted claim than most TikTok peptide content makes, and it is worth scrutinizing directly. The overall arc of the video is: supply more NAD+, slow its degradation, and increase cellular demand for it simultaneously. That is a plausible framework. Whether the evidence supports each leg of that stool is another question.

Does the science back this up?

Partially, with meaningful caveats. The NAD+ precursor biology is real and well-documented. MOTS-c as an AMPK activator is supported in rodent and some early human data. The 5-Amino-1MQ and NNMT connection is real but almost entirely preclinical. Calling this stack "synergistic" is a hypothesis, not an established finding.

On NAD+: declining NAD+ with age is documented in humans (Yoshino et al., 2021, Science). Supplementing NAD+ precursors like NR or NMN raises blood NAD+ levels, though tissue-level and functional effects are inconsistent across trials. Injecting NAD+ directly, as implied here, is a different delivery route with its own absorption questions.

On MOTS-c: a 2021 paper by Reynolds et al. in Nature Aging showed MOTS-c improved insulin sensitivity and exercise capacity in older men, which is promising. MOTS-c does activate AMPK. Derek's claim that it produces "more mitochondria" refers to mitochondrial biogenesis, which is downstream of AMPK activation, but that chain of causation in humans is not as clean as he makes it sound.

On 5-Amino-1MQ: the NNMT-inhibition mechanism is real. Neelakantan et al. (2019, Nature Communications) showed NNMT inhibition in mice reduced fat mass and raised NAD+ in adipose tissue. But this is mouse data. Human trials for 5-Amino-1MQ do not exist in the published literature as of this writing.

What did they get wrong (or right)?

The biggest overreach is the fat loss claim. Saying NNMT levels "tend to be rising" during a fat loss stall implies a clinically observed pattern in humans. The evidence for that comes from metabolic disease research in mice and obese patient tissue samples, not from lean people hitting a diet plateau.

Derek also says MOTS-c is "producing more mitochondria," which collapses a multi-step biological process into a clean soundbite. AMPK activation can promote mitochondrial biogenesis via PGC-1 alpha, but "MOTS-c injection equals more mitochondria" skips several conditional steps that may or may not fire in a given individual.

What he got right: the NNMT-to-NAD+ connection is mechanistically accurate. The role of NAD+ in ATP synthesis is textbook correct. And framing 5-Amino-1MQ as a conservation strategy rather than a direct NAD+ booster is actually a nuanced and accurate distinction that most influencer content misses entirely. Credit where it is due.

What should you actually know?

This stack sits at the edge of evidence. Two of the three compounds lack robust human clinical trial data at the doses implied in peptide therapy contexts. MOTS-c has the strongest emerging human data, but it is still early. 5-Amino-1MQ is almost entirely preclinical. NAD+ supplementation has human data, but the delivery method matters and direct NAD+ infusion or injection is not the same as taking an oral precursor.

Anyone considering this blend should know that "synergistic" is a marketing word until a combination study proves it. No published trial has tested all three compounds together in humans. The individual mechanisms may each be real, but stacking three compounds with overlapping metabolic targets also stacks the unknowns, including potential off-target effects on AMPK signaling pathways that regulate more than just energy.

• NNMT inhibition affects methylation balance, not just fat metabolism, and those downstream effects are not fully characterized in humans.
• MOTS-c is a peptide requiring injection, with no established standardized dosing protocol in clinical literature.
• NAD+ levels can be measured, which means baseline testing before any intervention is a reasonable starting point, not an optional step.

If you are interested in this area, the conversation should start with a clinician who can order labs, not a TikTok stack recommendation.